Nanoparticle-mediated gene delivery to tumour neovasculature.
The alpha(v)beta(3) integrin is a potential pharmacological target for anti-angiogenic therapy. A recent report describes the use of alpha(v)beta(3)-targeted nanoparticles to deliver a gene to tumour vasculature selectively. This resulted in substantial tumour regression in several experimental mouse tumour models. Hence, this approach has great potential for the treatment of human cancer.
Reynolds
Andrew R
AR
Cell Adhesion and Disease Laboratory, Cancer Research UK, Richard Dimbleby Department of Cancer Research, St. Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK.
Moein Moghimi
S
S
Hodivala-Dilke
Kairbaan
K
D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000818:Animals; D018014:Gene Transfer Techniques; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000378:metabolism*; D008958:Models, Molecular; D036103:Nanotechnology; D009369:Neoplasms / Q000098:blood supply* / Q000628:therapy*; D009389:Neovascularization, Pathologic
D020533:Angiogenesis Inhibitors; D039302:Integrin alphaVbeta3